This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zanetta, G. Articles by Mangioni, C. Search for Related Content PubMed PubMed Citation Articles by Zanetta, G. Articles by Mangioni, C. Social Bookmarking                            What's this?

Survival and Reproductive Function After Treatment of Malignant Germ Cell Ovarian Tumors

By Gerardo Zanetta, Cristina Bonazzi, Maria Grazia Cantù, Sergio Bini, Anna Locatelli, Giorgio Bratina, Costantino Mangioni

From the Department of Obstetrics and Gynecology and Department of Pathology, San Gerardo Hospital of Monza, University of Milano, Bicocca, Italy.

Address reprint requests to Gerardo Zanetta, MD, Department of Obstetrics and Gynecology, Ospedale San Gerardo, Via Solferino 16, 2 Monza Italy, 2005; email: gzanetta{at}iol.it

PURPOSE: Germ cell ovarian tumors are curable. The possible sequelae of chemotherapy on long-term survivors are still unknown, but these patients may expect normal lives. The aim of this study was to evaluate the outcome and reproductive function in a population of women treated since 1982.

MATERIALS AND METHODS: Between 1982 and 1996, 169 women with malignant germ cell ovarian tumors were seen (70 dysgerminomas, 28 endodermal sinus tumors, 24 mixed tumors, and 47 immature teratomas). Seventy-one had advanced or recurrent disease. Fertility-sparing surgery was performed in 138 (81%) women, 81 of whom received postoperative chemotherapy.

RESULTS: With a median follow-up of 67 months, the survival rate was 94% for dysgerminoma, 89% for endodermal sinus tumors, 100% for mixed types, and 98% for immature teratoma. For women who were treated conservatively, the survival rate was 98%, 90%, 100%, and 100%, respectively. Two women had adnexal recurrences, and both received salvage treatment. After treatment, all but one postpubertal woman had recovery of menses within 9 months. During follow-up, 12 untreated and 20 treated patients had 55 conceptions. We recorded 40 pregnancies at term, six terminations, and nine miscarriages. Four malformations were observed: one in 14 conceptions of patients who had not received chemotherapy and three in 41 conceptions of treated patients.

CONCLUSION: Irrespective of subtype and stage, conservative surgery should become the standard approach to treating most patients with malignant ovarian germ cell tumors. Fertility seems to be only marginally affected by treatments. Miscarriages are in the expected range for the general population. The malformation rate is slightly higher than in the general population, but no significant difference was seen between patients who did and did not receive chemotherapy.

Deceased.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Ellis and T. Mould Fertility-saving treatment in gynaecological oncology Obstet Gynaecol (Lond), October 1, 2009; 11(4): 239 - 244. [Abstract] [Full Text] [PDF]

				T. de La Motte Rouge, P. Pautier, P. Duvillard, A. Rey, P. Morice, C. Haie-Meder, P. Kerbrat, S. Culine, F. Troalen, and C. Lhomme Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor Ann. Onc., August 1, 2008; 19(8): 1435 - 1441. [Abstract] [Full Text] [PDF]

				D. M. Gershenson Management of Ovarian Germ Cell Tumors J. Clin. Oncol., July 10, 2007; 25(20): 2938 - 2943. [Abstract] [Full Text] [PDF]

				D. M. Gershenson, A. M. Miller, V. L. Champion, P. O. Monahan, Q. Zhao, D. Cella, and S. D. Williams Reproductive and Sexual Function After Platinum-Based Chemotherapy in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study J. Clin. Oncol., July 1, 2007; 25(19): 2792 - 2797. [Abstract] [Full Text] [PDF]

				Y. Kitajima, T. Endo, T. Hayashi, S. Ishioka, T. Baba, H. Honnma, and T. Saito A successful IVF-pregnancy in a patient who underwent conservative surgery followed by a regimen of cisplatin, vinblastine and peplomycin to treat an advanced ovarian mixed germ cell tumour: A Case Report Hum. Reprod., March 1, 2007; 22(3): 850 - 852. [Abstract] [Full Text] [PDF]

				N. Murugaesu, P. Schmid, G. Dancey, R. Agarwal, L. Holden, I. McNeish, P. M. Savage, E. S. Newlands, G. J.S. Rustin, and M. J. Seckl Malignant Ovarian Germ Cell Tumors: Identification of Novel Prognostic Markers and Long-Term Outcome After Multimodality Treatment J. Clin. Oncol., October 20, 2006; 24(30): 4862 - 4866. [Abstract] [Full Text] [PDF]

				S. J. Lee, L. R. Schover, A. H. Partridge, P. Patrizio, W. H. Wallace, K. Hagerty, L. N. Beck, L. V. Brennan, and K. Oktay American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients J. Clin. Oncol., June 20, 2006; 24(18): 2917 - 2931. [Abstract] [Full Text] [PDF]

				M. M. Leitao Jr and D. S. Chi Fertility-Sparing Options for Patients with Gynecologic Malignancies Oncologist, September 1, 2005; 10(8): 613 - 622. [Abstract] [Full Text] [PDF]

				D. M. Gershenson Fertility-Sparing Surgery for Malignancies in Women J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 43 - 47. [Abstract] [Full Text] [PDF]

				M. Sonmezer and K. Oktay Fertility preservation in female patients Hum. Reprod. Update, May 1, 2004; 10(3): 251 - 266. [Abstract] [Full Text] [PDF]